Tuesday, Moderna, Inc. (MRNA) announced several significant changes to its operating model to support its short- and long-term business goals to become a diversified, multi-modality biotechnology company.
As part of the move, the company plans the potential launch of up to three new products in 2027 and 2028, including flu plus COVID combination, seasonal flu and norovirus vaccines. It also expects important clinical milestones this year, including potential pivotal data readouts for its investigational individualized neoantigen therapy and rare genetic disease propionic acidemia therapeutic.
In light of these plans, Stephen Hoge, President of Moderna, will assume oversight of operational and cross-functional leadership across Research & Development, Manufacturing and Commercial for the Company's three franchises. Additionally, Ester Banque was appointed as the company's Chief Commercial Officer, effective June 15, 2026.
Further, the company stated that it will continue to invest in mRED, its innovation engine focused on advancing new modalities through clinical proof of concept and creating the next wave of growth beyond its current portfolio.
Currently, MRNA is trading at $53.67, up 2.90 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.